Clinical Care Options Oncology - Leukemia http://clinicaloptions.com/Oncology.aspx New treatment data and educational activities for Oncology and Hematology Clinicians en-us Clinical Care Options Oncology - Leukemia http://images.imedoptions.com/img.asp?img=cco/CCO_ONC_RSS.gif http://clinicaloptions.com/oncology Management of a 69-Year-Old Patient With Deletion 5q Myelodysplastic Syndromehttp://clinicaloptions.com/Oncology/Treatment%20Updates/MDS%20Treatment/Interactive%20Case%20Challenges/Case%202.aspxAlan F. List, MD, reviews treatment options for a patient with del(5q) MDS. Clinical Management of a 69-Year-Old Man With Intermediate-1-Risk Myelodysplastic Syndromehttp://clinicaloptions.com/Oncology/Treatment%20Updates/MDS%20Treatment/Interactive%20Case%20Challenges/Case%201.aspxIn this Interactive Case Challenge, Azra Raza, MD, and Naomi Galili, PhD, discuss treatment options for a patient with intermediate-risk myelodysplastic syndrome and monosomy of chromosome 7. Slideset Module: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007.aspxDownload a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications. Expert Analysis: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Expert%20Analysis.aspxMoshe Talpaz, MD; Brian Druker, MD; Charles L. Sawyers, MD; and Allen Yang, MD, PhD, review clinical data on chronic myeloid leukemia presented at the 2007 hematology meeting. Expert Recap: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Virtual%20Presentation%20Programs/CML/CML%20ER.aspxWatch and listen as Moshe Talpaz, MD, reviews the latest data on chronic myeloid leukemia treatment presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Expert Recap: Chronic Lymphocytic Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Virtual%20Presentation%20Programs/CLL/CLL.aspxIn this Expert Recap, Michael J. Keating, MB BS, reviews the most up-to-date data on chronic lymphocytic leukemia presented at the 2007 annual hematology meeting in Atlanta, Georgia. Expert Analysis: Chronic Lymphocytic Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CLL/Expert%20Analysis.aspxJohn C. Byrd, MD, Michael J. Keating, MB BS, and Kanti Rai, MD, discuss the latest clinical data on treatment of chronic lymphocytic leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Roy A. Beveridge, MD. Expert Analysis: Acute Leukemiashttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Expert%20Analysis.aspxHagop M. Kantarjian, MD; Dan Douer, MD; and Stephen J. Forman, MD, discuss the latest clinical data on treatment of acute leukemias presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Mark Kirschbaum, MD. Expert Analysis: Myelodysplastic Syndromeshttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/MDS/Expert%20Analysis.aspxRead a discussion among Alan F. List, MD; Lewis R. Silverman, MD; and Azra Raza, MD, and moderated by Allan S. Yang, MD, PhD, on the key studies presented at ASH 2007 regarding treatment and pathogenesis of myelodysplastic syndromes. Pretransplant Imatinib During First Chronic Phase Associated With Improved Survival in CMLhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/738.aspxPatients with CML in first chronic phase treated with imatinib prior to HSCT have improved survival vs patients who do not receive imatinib Nilotinib Active and Safe in Patients With Imatinib-Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/735.aspx18-month survival rate of 91% among patients with imatinib-resistant/intolerant chronic-phase chronic myeloid leukemia treated with nilotinib Bosutinib Active and Well Tolerated in Heavily Pretreated Patients With Chronic-Phase CMLhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/733.aspxNovel dual TKI of ABL and Src, bosutinib, induces responses in patients with treatment-experienced chronic-phase CML after previous TKI treatment failure INNO-406 Active and Well Tolerated in Patients With Ph-Positive CML and ALL Who Have Failed Multiple Tyrosine Kinase Inhibitorshttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/469.aspxINNO-406, novel dual Bcr-Abl/Lyn kinase inhibitor, demonstrates activity in imatinib-resistant/intolerant CML and ALL population Low Sensitivity BCR-ABL Mutants Identified in Vitro Correspond With Reduced Response to Dasatinib in Patients With Chronic-Phase CMLhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/319.aspxSensitivity of BCR-ABL mutants to dasatinib corresponds to hematologic and cytogenetic response rates in patients with chronic-phase CML. Dasatinib Induces High Response Rates and Is Well Tolerated in Treatment-Naive Patients With Early CP CML http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/30.aspx In this study, most patients with treatment-naive, early chronic-phase chronic myeloid leukemia achieved complete cytogenetic response after 18 months of dasatinib therapy Response to Imatinib Sustained in 6-Year Follow-up With Continued Safety in Newly Diagnosed Chronic-Phase CML http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/25.aspx Results of 6-year follow-up study demonstrate continued safety and efficacy of imatinib therapy in chronic-phase CML. Time to Complete Cytogenetic Response Does Not Predict Outcomes in Chronic-Phase CML Treated With Imatinib http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/27.aspx Complete cytogenetic response to imatinib in patients with newly diagnosed chronic-phase CML was associated with excellent outcomes, regardless of when the response was achieved. Responses to Dasatinib in Patients With Imatinib-Resistant/Intolerant Chronic-Phase CML Maintained in 2-Year Follow-up of START-C Trial http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/734.aspx Twenty-four month follow-up data show that dasatinib is effective in patients with imatinib-resistant or imatinib-intolerant chronic-phase CML. Addition of Imatinib Did Not Affect Survival in Patients With Ph-Positive ALL in Preliminary Analysis of UK Study http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/8.aspx In the UKALLXII/ECOG 2993 trial, imatinib did not appear to improve overall or event-free survival in patients with Ph-positive ALL when compared with a historic preimatinib cohort from the same study Dose-Intense Pediatric Regimen May Improve Outcomes in Adults With Newly Diagnosed ALL http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/587.aspx A dose-intense pediatric chemotherapy regimen appears feasible and effective in adult ALL. Dasatinib Superior to High-Dose Imatinib in Patients With Imatinib-Resistant Chronic-Phase Chronic Myeloid Leukemia After 2-Year Follow-up http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/736.aspx 2-year follow-up reveals that dasatinib therapy among patients with chronic-phase chronic myeloid leukemia is associated with superior responses and PFS compared with high-dose imatinib ASCT-Whether From Siblings or Unrelated Donors--Benefits Patients With High-Risk AML in First CR http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/169.aspx In patients with high-risk AML in first CR, survival improved following ASCT, regardless of unrelated vs sibling donors In AML, Idarubicin Induction Produces More CRs Than High-Dose Daunorubicin Whereas IL-2 in Maintenance Therapy Offers No Clear Survival Benefit http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/162.aspx In AML induction therapy, idarubicin produces more and earlier CRs than high-dose daunorubicin whereas maintenance IL-2 failed to improve DFS Rituximab-Containing Modified HyperCVAD Regimen Improves DFS in CD20-Positive Younger Adult Patients With ALL http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/2824.aspx Rituximab addition to modified hyper-CVAD improves DFS but not OS in younger adult patients with ALL. Imatinib Added to HyperCVAD Demonstrates Favorable 3-Year DFS and OS in Acute Lymphoblastic Leukemia http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/9.aspx HyperCVAD plus imatinib therapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia superior to hyperCVAD alone. CD20 Expression Associated With Poor Outcome in Adult Patients With B-Cell Precursor ALL http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/2829.aspx In adult B-cell precursor acute ALL, patients with CD20 expression have higher relapse rates than CD20-negative counterparts. Patients With AML Often Do Not Opt for Consolidation Recombinant IL-2, Despite Possible Therapeutic Benefit http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/157.aspx Whereas recombinant IL-2 may offer therapeutic benefit in AML in first CR after completion of all planned chemotherapy, many patients often decline to use it or discontinue use early. In AML, Complete Response, Strictly Defined, Predicts Increased Long-term Survival After Cytarabine Induction http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Capsules/298.aspx New paradigms of response notwithstanding, survival to 3 years and beyond in patients with AML treated with cytarabine induction is uncommon without standard CR.